Objectives To develop and validate a preoperative multimodal model that predicts a high-risk recurrence phenotype indicative of poor disease-free survival (DFS), in order to stratify patients with stage IA non-small cell lung cancer (NSCLC). Materials and methods This retrospective multicenter study enrolled 342 stage IA NSCLC patients from three independent centers. The high-risk recurrence phenotype (indicative of poor DFS) was defined by postoperative pathology as the presence of spread through air spaces (STAS), lymphovascular invasion (LVI), a predominant solid/micropapillary/complex glandular pattern, or a > 5% solid/micropapillary component. Deep learning features were extracted from preoperative biopsy whole-slide images (WSI) using the UNI foundation model, and CT morphological and textural features were extracted from preoperative chest CT. An early-fusion multimodal model integrating clinical, radiomics, and pathomics features was developed and evaluated with five-fold cross-validation. The Kaplan–Meier method with log-rank tests was used to assess associations between the model-predicted risk and DFS. Logistic regression identified clinical predictors of high-risk pathology. Model interpretability and clinical utility were examined with SHapley Additive exPlanations (SHAP) and calibration analysis, respectively. Results The multimodal model achieved higher discriminative performance than each single-modality model in both the internal and external test sets. In the internal test set, it yielded an AUC of 0.76 (95% CI 0.58-0.90); in external validation, AUCs were 0.69 (95% CI 0.55-0.82) in Center 2 and 0.86 (95% CI 0.74-0.96) in Center 3. Multivariable analysis identified solid tumor density as the only independent predictor (OR = 5.13, 95% CI 1.53-17.24; P = 0.008). Model-stratified high-risk patients showed significantly inferior DFS in both the training (2-year DFS 78% vs. 99%; log-rank P < 0.0001) and external (3-year DFS 86% vs. 100%; log-rank P = 0.003) cohorts. Conclusion The multimodal model consistently predicted the high-risk recurrence phenotype across multiple centers. This phenotype may serve as a pragmatic indicator of poor DFS to guide earlier individualized treatment decisions, including adjuvant therapy and intensified surveillance, in stage IA NSCLC.
L. Lai, Yanji Wang, Jiangle Jiang et al.· Frontiers in Immunology· 0 citations
Background: Reliability-aware integration of heterogeneous data sources remains a fundamental challenge in multimodal deep learning: prevailing fusion strategies assume uniform reliability across sources and instances, limiting their responsiveness to data-dependent trustworthiness. Methods: We introduce REM-Fuse (Reliability-aware Evidential Multimodal Fusion), an evidential deep learning (EDL) framework in which per-source Dirichlet uncertainty adaptively weights each source through dual-channel weighting, asymmetric cross-scale enhancement, and Dempster–Shafer-inspired evidence accumulation. As a case study for cancer prognosis, REM-Fuse integrates multi-scale histopathology (10×, 20×) and RNA-seq on TCGA-BRCA (n = 831) via five-fold cross-validation with subtype- and stage-stratified analyses. Results: REM-Fuse attained a concordance index of 0.715 and a 60-month time-dependent AUC of 0.729, indicating moderate discrimination and significant risk separation (log-rank p < 0.001). Adaptive source weights and per-patient uncertainty varied significantly across molecular subtypes (Kruskal–Wallis p = 0.010 and p = 0.007), indicating patient-specific rather than fixed multimodal integration. Conclusions: REM-Fuse provides a compact reliability-aware fusion strategy for cancer prognosis, although external validation is needed before broader clinical or cross-cohort generalization.
Yalu Huang, Yushuai Yuan, Wenbin Ye et al.· Mathematics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.